Alpha Cognition

ACOG

Market cap $141M

Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Alpha Cognition Inc. (ACOG) Discusses Commercial Adoption Metrics and Market Opportunity in Long-Term Care Transcript

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Alpha Cognition will participate in an upcoming virtual fireside chat hosted by Boris Peaker of Titan Partners. The discussion will focus on commercialization efforts and research initiatives to accelerate commercial adoption. Presentation.

Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Dallas, Texas--(Newsfile Corp. - November 14, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition completed its second quarter of ZUNVEYL® commercialization in 3Q25, with launch momentum accelerating across the U.S. long-term care (LTC) channel.

Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.31 per share a year ago.

Alpha Cognition Inc. ( ACOG ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Henry Du - VP of Finance & Accounting and Interim CFO Michael McFadden - CEO & Director Lauren D'Angelo - Chief Operating Officer Conference Call Participants Boris Peaker David Storms - Stonegate Capital Partners, Inc., Research Division Presentation Operator Greetings. Welcome to Alpha Cognition's Earnings Conference Call.

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”) today announced its financial results for the third quarter ended September 30, 2025, and provided an operational update. “Our performance this quarter reinforces our belief in the strength of our long term care focused call strategy and reflects disciplined execution across the organization,” said Michael McFadden, Chief Executive Officer of Alpha Cognition.

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its third quarter financial results and business highlights on that date. The financial.

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at two upcoming scientific meetings: the American Society of Consultant Pharmacists (ASCP) Annual Meeting (October 23–25, 2025) and the Neuroscienc.